His company has already produced more than 20 million doses of the vaccine and expects that figure to have reached 50 million by the end of the year. Another 1.3 billion doses are planned to be manufactured in 2021.How will a vaccine be administered? What about adverse reactions?
However, Mr Bourla confirmed his company would react to each decision in turn - meaning that the faster a country grants regulatory approval, the faster it would receive the vaccine. With each person requiring two doses of the vaccine for it to be effective, the company's estimate of 1.3bn doses by the end of 2021 would only cover around 9% of the world's population. So, would he consider sharing production with rival companies?"It is very challenging to transfer manufacturing to GSK or Sanofi. It's not that easy. But we will explore any possible avenue. That will need to involve other manufacturing networks of other corporations.
"I don't think it's a secret that our company, together with all the corporate world, was not fascinated with the idea that the UK will separate from Europe, but it is the will of the United Kingdom's people and we have been working for years now to come to a solution when this transition happens," he said.
"Everybody started discussing scientific topics with political instead of scientific terms, and people got confused. They didn't know who to believe, or what to believe, and that is the situation we face right now.Pfizer boss interview in full on new vaccine My last question to him was about his own reflections, about the process of leading Pfizer, a company valued at more than $200bn, over this tumultuous year.